HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ONO 6818

structure in first source

Also Known As:

ONO-6818

Networked: 6 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxadiazoles: 146
        ONO 6818: 6
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - ONO 6818: 6

Experts

1.	Fujita, Tsuneo: 2 articles (02/2005 - 10/2004)
2.	Hirota, Yasushi: 2 articles (02/2005 - 10/2004)
3.	Katsube, Nobuo: 2 articles (02/2005 - 10/2004)
4.	Suzuki, Mikie: 2 articles (02/2005 - 10/2004)
5.	Yamaguchi, Kojiro: 2 articles (02/2005 - 10/2004)
6.	Ishibashi, Masayoshi: 1 article (08/2002)
7.	Kuraki, Takashige: 1 article (08/2002)
8.	Shiraishi, Motokimi: 1 article (08/2002)
9.	Takayama, Masanori: 1 article (08/2002)
10.	Yoshida, Minoru: 1 article (08/2002)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 08/01/2002 - "ONO-6818 was in phase I studies for COPD in Japan as of December 1999 [366431]. " 08/01/2002 - "ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and chronic obstructive pulmonary disease (COPD) [174095]. " 07/01/2002 - "In the application of chronic obstructive pulmonary disease therapy, the human neutrophil elastase inhibitors mainly focused upon include ONO-5046, MR-889, L-694,458, CE-1037, GW-311616 and TEI-8362 as the acyl-enzyme inhibitors; and ONO-6818, AE-3763, FK-706, ICI-200,880, ZD-0892 and ZD-8321 as the transition-state inhibitors. "
2.	Colitis 02/01/2005 - "In the subcutaneous treatment study, ONO-6818 was administered once before the induction of colitis. " 02/01/2005 - "The inhibitory effects on the ulcer area and NE activity were confirmed after oral treatment with ONO-6818 after induction of colitis. " 10/01/2004 - "We investigated the effects of an orally active NE inhibitor, ONO-6818, on acetic acid induced colitis in Syrian hamsters. "
3.	Ulcer 02/01/2005 - "Although ONO-6818 had little effect on the tissue MPO activity, the ulcer area and NE activity were decreased in the ONO-6818-treated group. " 02/01/2005 - "The inhibitory effects on the ulcer area and NE activity were confirmed after oral treatment with ONO-6818 after induction of colitis. " 10/01/2004 - "Either oral or subcutaneous treatment with ONO-6818 had significant inhibitory effects on the ulcer area, hemoglobin level and NE activity in the colonic lumen, but ONO-6818 did not have a significant inhibitory effect on tissue MPO activity. "
4.	Acute Lung Injury 08/15/2002 - "ONO-6818 inhibited acute lung injury induced by HNE by minimizing lung hemorrhage and accumulation of neutrophils in the lung. "
5.	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/01/2002 - "ONO-6818 (CP-955) is the lead compound in a series of orally bioavailable neutrophil elastase inhibitors licensed from Cortech and under investigation by Ono for the potential treatment of inflammatory conditions, such as rheumatoid arthritis, inflammatory bowel disease and chronic obstructive pulmonary disease (COPD) [174095]. "

Related Drugs and Biologics

1.	Secretory Proteinase Inhibitory Proteins
2.	Acetic Acid (Vinegar)
3.	Hemoglobins (Hemoglobin)
4.	Enzyme Inhibitors (Inhibitors, Enzyme)
5.	N- ((3- (carboxymethyl)- 2- oxoimidazolidin- 1- yl)acetyl)- l- valyl- N- ((3S)- 1,1,1- trifluoro- 4- methyl- 2- oxopentan- 3- yl)- l- prolinamide
6.	TEI 8362
7.	ZD 0892
8.	ZD 8321
9.	DMP 777
10.	MDL 201,404YA

Related Therapies and Procedures

1.	Therapeutics